甘氨双唑钠联合放疗治疗鼻咽癌Meta分析

发布时间：2018-06-08 00:16

本文选题：甘氨双唑钠 + 鼻咽癌　；参考：《中华肿瘤防治杂志》2014年17期

【摘要】：目的:评价甘氨双唑钠(metronidazole amino acidum natrium,CMNa)作为放疗增敏剂治疗鼻咽癌的疗效与安全性。方法:利用计算机检索Cochrane Library、PubMed、EMbase、中国生物医学文献数据库(CBM)、中国学术期刊全文数据库(CNKI)、中国科技期刊数据库(VIP)和万方数字化期刊全文数据库,同时配合其他检索,收集CMNa联合放疗治疗鼻咽癌的随机对照试验(randomized controlled trial,RCT)。按纳入和排除标准筛选文献、提取资料和质量评价后,利用RevMan 5.1软件进行Meta分析。结果:共纳入16个RCT。在近期疗效方面,CMNa联合放疗对比单纯放疗治疗鼻咽癌,患者的原发灶(OR=3.14,95%CI为2.15~4.61,P0.001)、颈部淋巴结转移灶(OR=2.48,95%CI为1.60~3.83,P0.001)和原发灶复发(OR=3.44,95%CI为1.72~6.84,P0.001)差异均有统计学意义;对比单纯放疗疗法,CMNa联合放疗疗法的1(OR=4.94,95%CI为2.41~10.15,P0.001)、3(OR=2.42,95%CI为1.31~4.50,P=0.005)和5年生存率(OR=2.04,95%CI为1.1 7~3.55,P=0.010)差异也有统计学意义;在恶心呕吐、白细胞降低和影响肝功能等不良反应方面,2组差异均无统计学意义,P0.05。结论:CMNa作为放疗增敏剂治疗鼻咽癌,可以改善患者的近期疗效和生存率,并不增加放疗的毒副作用,在临床上具有一定的应用价值。
[Abstract]:Aim: to evaluate the efficacy and safety of metronidazole amino acidum natriumn (CMNa) as a radiosensitizer in the treatment of nasopharyngeal carcinoma (NPC). Methods: computer search was used to retrieve Cochrane Library PubMedbase, Chinese Biomedical Literature Database (CBMN), Chinese academic Journals full text Database (CNKI), Chinese Sci-tech Journals Database (VIPB) and Wanfang Digital Journal Full-text Database. A randomized controlled trial of CMNa combined with radiotherapy for nasopharyngeal carcinoma (NPC) was conducted. The literature was screened according to the inclusion and exclusion criteria, the data was extracted and the quality was evaluated. The Meta-analysis was carried out by Revman 5.1 software. Results: 16 RCTs were included. In the short-term curative effect, compared with radiotherapy alone, there were significant differences between the primary tumor OR3.1495CI 2.15V 4.61g P0.001, the cervical lymph node metastasis 2.48995 CI 1.600.83.83n P0.001) and the primary tumor recurrence OR3.44995CI 1.72m6.844p 0.001. There was significant difference between the two groups in the treatment of nasopharyngeal carcinoma (P 0.001). The results showed that there were significant differences between the two groups in the treatment of nasopharyngeal carcinoma (OR3.44995 CI = 1.72P 0.001), the cervical lymph node metastasis (OR 2.4895 CI = 1.72P 0.001, P 0.001). There was also a significant difference in CI between CMNa and CMNa combined radiotherapy (CI = 2.41 10. 15, P 0.001, P 0.001) and 5-year survival rate (OR2.04 + 95CI = 1.173.55P0.010), while there was no significant difference in adverse reactions, such as nausea and vomiting, leukopenia and influence of liver function, between the two groups (P 0.05), and the difference between the two groups was not statistically significant (P < 0.05), but there was no significant difference between the two groups in terms of adverse reactions, such as nausea and vomiting, leukopenia, and influence on liver function, and the 5-year survival rate was 1.73.55P0.010), and there was no significant difference between the two groups in terms of adverse reactions such as nausea and vomiting, leukopenia and liver function. Conclusion as a radiosensitizer, WCMNa can improve the short-term curative effect and survival rate of patients with nasopharyngeal carcinoma, and does not increase the toxicity and side effects of radiotherapy. It has certain clinical application value.
【作者单位】：兰州大学第一医院耳鼻咽喉头颈外科;
【基金】：甘肃省卫生厅行业科技计划(GSWST2011-06) 甘肃省中医药科学技术研究课题(GIK-2011-22)
【分类号】：R739.63

【相似文献】